Morgan Stanley Upgrades Mylan (MYL) to Overweight, Downgrades Watson (WPI) to Equalweight
Tweet
Share
E-mailGet Alerts MYL Hot Sheet
Price: $15.86 --0%
Rating Summary:
17 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
17 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Shares of Mylan (NYSE: MYL) and Watson Pharma (NYSE: WPI) are moving in opposite directions this afternoon following intraday calls from an analyst at Morgan Stanley.
An analyst at the firm upgraded shares of Mylan while at the same time downgrading shares of Watson Pharma. Morgan Stanley now rates Mylan shares an Overweight, up from Equalweight previously, and shares of Watson an Equalweight, down from a prior Overweight rating.
Mylan shares are up 4.3 percent to $19.29 at last check; shares of Watson are down 3.9 percent to $64.70.
The Morgan Stanley call follows Watson's launch of generic lipitor Wednesday morning.
An analyst at the firm upgraded shares of Mylan while at the same time downgrading shares of Watson Pharma. Morgan Stanley now rates Mylan shares an Overweight, up from Equalweight previously, and shares of Watson an Equalweight, down from a prior Overweight rating.
Mylan shares are up 4.3 percent to $19.29 at last check; shares of Watson are down 3.9 percent to $64.70.
The Morgan Stanley call follows Watson's launch of generic lipitor Wednesday morning.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Downgrades oOh!media (OML:AU) to Equalweight
- HSBC Downgrades Gerdau S.A. (GGBR4:BZ) (GGB) to Hold
- JPMorgan Downgrades Kuaishou Technology (1024:HK) to Neutral
Create E-mail Alert Related Categories
Downgrades, UpgradesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
